BACKGROUND: Cholesterol 24S-hydroxylase (CYP46) catalyzes the conversion of cholesterol to 24S-hydroxycholesterol, the primary cerebral cholesterol elimination product. Only few gene variations in CYP46 gene (CYP46A1) have been investigated for their relevance as genetic risk factors of Alzheimer's disease (AD) and results are contradictory. METHODS: We performed a gene variability screening in CYP46A1 and investigated the effect of gene variants on the risk of AD and on CSF levels of cholesterol and 24S-hydroxycholesterol. RESULTS: Two of the identified 16 SNPs in CYP46A1 influenced AD risk in our study (rs7157609: p=0.016; rs4900442: p=0.019). The interaction term of both SNPs was also associated with an increased risk of AD (p=0.006). Haplotypes including both SNPs were calculated and haplotype G-C was identified to influence the risk of AD (p=0.005). AD patients and non-demented controls, who were carriers of the G-C haplotype, presented with reduced CSF levels of 24S-hydroxycholesterol (p=0.001) and cholesterol (p<0.001). CONCLUSION: Our results suggest that CYP46A1 gene variations might act as risk factor for AD via an influence on brain cholesterol metabolism.
BACKGROUND:Cholesterol 24S-hydroxylase (CYP46) catalyzes the conversion of cholesterol to 24S-hydroxycholesterol, the primary cerebral cholesterol elimination product. Only few gene variations in CYP46 gene (CYP46A1) have been investigated for their relevance as genetic risk factors of Alzheimer's disease (AD) and results are contradictory. METHODS: We performed a gene variability screening in CYP46A1 and investigated the effect of gene variants on the risk of AD and on CSF levels of cholesterol and 24S-hydroxycholesterol. RESULTS: Two of the identified 16 SNPs in CYP46A1 influenced AD risk in our study (rs7157609: p=0.016; rs4900442: p=0.019). The interaction term of both SNPs was also associated with an increased risk of AD (p=0.006). Haplotypes including both SNPs were calculated and haplotype G-C was identified to influence the risk of AD (p=0.005). ADpatients and non-demented controls, who were carriers of the G-C haplotype, presented with reduced CSF levels of 24S-hydroxycholesterol (p=0.001) and cholesterol (p<0.001). CONCLUSION: Our results suggest that CYP46A1 gene variations might act as risk factor for AD via an influence on brain cholesterol metabolism.
Authors: Timothy J Hohman; Jessica N Cooke-Bailey; Christiane Reitz; Gyungah Jun; Adam Naj; Gary W Beecham; Zhi Liu; Regina M Carney; Jeffrey M Vance; Michael L Cuccaro; Ruchita Rajbhandary; Badri Narayan Vardarajan; Li-San Wang; Otto Valladares; Chiao-Feng Lin; Eric B Larson; Neill R Graff-Radford; Denis Evans; Philip L De Jager; Paul K Crane; Joseph D Buxbaum; Jill R Murrell; Towfique Raj; Nilufer Ertekin-Taner; Mark W Logue; Clinton T Baldwin; Robert C Green; Lisa L Barnes; Laura B Cantwell; M Daniele Fallin; Rodney C P Go; Patrick Griffith; Thomas O Obisesan; Jennifer J Manly; Kathryn L Lunetta; M Ilyas Kamboh; Oscar L Lopez; David A Bennett; John Hardy; Hugh C Hendrie; Kathleen S Hall; Alison M Goate; Rosalyn Lang; Goldie S Byrd; Walter A Kukull; Tatiana M Foroud; Lindsay A Farrer; Eden R Martin; Margaret A Pericak-Vance; Gerard D Schellenberg; Richard Mayeux; Jonathan L Haines; Tricia A Thornton-Wells Journal: Alzheimers Dement Date: 2015-06-16 Impact factor: 21.566